Hypertensive intra-arterial chemotherapy for endometrial carcinoma assessed by transvaginal doppler ultrasound and magnetic resonance imaging

We examined the effectiveness of hypertensive intra-arterial chemotherapy for endometrial carcinoma using transvaginal Doppler ultrasound and magnetic resonance imaging. Angiotensin II, 100 mg cisplatin, and 40 mg doxorubicin were prescribed for 8 patients with endometrial carcinoma (3 stage la; 3 stage Ib; 2 stage II). The resistance index (RI) was obtained for intratumoral blood flow velocity waveforms by transvaginal Doppler ultrasound and changes in RI (RI: differences before and after chemotherapy) were calculated. The tumor volume (TV) was also evaluated, based on the T2-weighted image of magnetic resonance imaging (MRI). The decrease in tumor size [DR-T: (TV before chemotherapy – TV after chemotherapy) / TV before chemotherapy × 100] was determined. RI measurements did not correlate with TV, either before or after chemotherapy. The ΔRI varied from 0.007 to 0.615 (mean: 0.207) and DR – T varied from 20.1% to 65.0% (mean: 45.5%). The correlation between ΔRI and DR – T [DR – T = 23.5 + 167.2 (ΔRI) – 165.6 (ΔRI)²; R² = 0.772, p < 0.05] was significant. Therefore, we confirmed the effectiveness of hypertensive intra-arterial chemotherapy for endometrial carcinoma using both transvaginal Doppler ultrasound and MRI. © 1995 John Wiley & Sons, Inc.     

选择性动脉内化疗治疗颅内恶性肿瘤的护理

目的:总结选择性动脉内化疗治疗颅内恶性肿瘤的护理经验。方法:对25例行选择性动脉内化疗的颅内恶性肿瘤患者,术前做好心理护理,术后严密观察。结果:25例行选择性动脉内化疗患者无1例发生不良反应。结论:神经介入选择性动脉内导管化疗术操作简单、用时短、创伤小、可重复,且能减轻化疗的不良反应,做好术前心理护理和术后监护,可收到较好疗效,值得临床推广使用。     

乳腺癌的血液供应及术前动脉灌注化疗

目的 探索乳腺癌的血液供应来源和术前动脉灌注化疗的方法及临床价值.方法 60例经穿刺细胞学诊断为乳腺癌的患者,经股动脉穿刺插管至患侧锁骨下动脉行数字减影动脉造影.观察乳腺和淋巴结内肿瘤血管、肿瘤染色及其血供来源.根据肿瘤血管多少及来源分别对胸廓内动脉、胸外侧动脉及锁骨下动脉灌注不同剂量的丝裂霉素、表柔比星和5-氟尿嘧啶.结果 47例(78.3%)乳腺内见肿瘤血管及肿瘤染色,67支动脉单独或参与乳腺内肿瘤供血,其中胸廓内动脉占56.7%(38/67),胸外侧动脉29.9%(20/67),腋动脉直接乳房支11.9%(8/67),肩胛下动脉1.5%(1/67).不间肿瘤部位、肿瘤分期和病理类型血供来源无统计学差异.2例纵隔淋巴结为胸廓内动脉供血,35例腋窝淋巴结染色者胸外侧动脉供血占75.6%,肩胛下动脉占24.4%.灌注后4周完全缓解(CR)3例(5%),部分缓解(PR)48例(80%),疾病稳定(SD)9例(15%).无严重并发症发生.结论 胸廓内动脉是乳腺内肿瘤的主要供血动脉,胸外侧动脉足腋窝淋巴结的主要供血动脉.术前动脉灌注化疗可缩小肿瘤体积,降低临床分期,提高保乳手术率.     

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma

ObjectiveTo compare the efficacy of sorafenib plus hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin to that of sorafenib alone in patients with advanced hepatocellular carcinoma (HCC).MethodsThis was a retrospective, single-center trial. Between April 3, 2017 and July 2, 2018, 104 patients with Child-Pugh A and advanced HCC received either 400 mg of sorafenib orally twice daily plus HAIC with oxaliplatin (oxaliplatin 85 mg/m², every 3 weeks via repetitive catheterization) (n = 46, soraOXA group) or 400 mg of only sorafenib orally twice daily (n = 58, sorafenib group). Overall survival, progression-free survival, objective response rate, and treatment-related adverse events were compared.ResultsThe median overall survival was 9.37 months (95% CI, 7.05–11.68) in the soraOXA group versus 4.8 months (95% CI, 2.98–6.62) in the sorafenib group (HR 0.46 [95% CI, 0.29–0.72]; P < 0.001). The soraOXA group also showed a higher objective response rate (16 [34.8%] vs 1 [1.7%]; P < 0.001) and a longer progression-free survival rate (5.5 months [95% CI, 2.32–8.68] vs 2.4 months [95% CI, 1.65–3.15], HR 0.54 [95% CI, 0.36–0.81], P = 0.003) than the sorafenib group. There was no significant difference in the overall incidence of any grade adverse events, grade 3/4 adverse events, serious adverse events, or incidence of treatment termination due to adverse events between the two groups.ConclusionCompared with sorafenib alone, sorafenib plus HAIC with oxaliplatin showed favorable treatment outcomes in patients with advanced HCC. The merits of this approach need to be established with a prospective trial.     

多西紫杉醇经动脉或静脉灌注对后肢VX2瘤兔的影响

目的 探讨多西紫杉醇经动脉灌注治疗肿瘤的有效性及安全性.方法 建立兔后肢VX2瘤动物模型.经股动脉或耳像静脉灌注多西紫杉醇.比较两种给药方式下实验兔的肿瘤组织、胃壁、肝脏、肾脏、血浆的药物浓度差异.采用t检验作统计学分析.结果 经动脉灌注组的肿瘤组织、胃壁、肝脏及肾脏的药物浓度均高于经静脉灌注组.肿瘤组织及胃壁中的药物浓度差异有统计学意义（P〈0.05）.肿瘤组织的药物浓度差别约为14倍.经动脉灌注组的血浆药物浓度低于经静脉灌注组,两者差异没有统计学意义（P〉0.05）.结论 多西紫杉醇经动脉灌注可提高肿瘤的局部控制效果,但有可能增加毒副反应发生的风险,应慎重采用或减少用药剂量.     

以雷替曲塞为基础经动脉灌注化疗的安全性和有效性分析

目的分析雷替曲塞经动脉灌注化疗的安全性和有效性。方法32例不同部位恶性肿瘤患者,采用介入方法,根据数字减影血管造影（DSA）提示,使用以雷替曲塞为基础的化疗方案,经肿瘤滋养动脉行灌注化疗。术后观察患者化疗不良反应和并发症,并对疗效进行评估。结果32例患者中2例出现Ⅱ一Ⅲ度骨髓抑制,发生率为6．25％,29例出现Ⅰ-Ⅱ度胃肠道反应,1例出现Ⅲ度胃肠道反应,发生率为3．13％,1例出现轻度腹泻。其他I度以上化疗相关不良反应未在本组病例中出现。所有患者均接受至少2次经动脉灌注化疗,完全缓解（CR）1例,部分缓解（PR）11例,病变稳定（SD）17例,病变进展（PD）3例,治疗的总有效率为90．63％。结论雷替曲塞用于动脉灌注化疗是安全、有效的。     

Intra-Arterial Chemotherapy for Retinoblastoma: A Collaborative Effort

Approximately 300 children in the United States are diagnosed yearly with retinoblastoma. For a generation, it has had the highest cure rate among pediatric solid tumors, allowing reduction in side effects of management to become important determinants of therapy. Priorities of treatment are saving life, eyes, and vision. Standard treatment involves enucleation, multiagent systemic chemotherapy, and radiation and intra-arterial chemotherapy (IAC). IAC is a treatment option to deliver chemotherapy locally to the eye while minimizing systemic exposure. Research in the treatment of retinoblastoma has led to new treatment protocols for children. The purpose of this article is to define retinoblastoma, introduce the goals and priorities of retinoblastoma treatment, and describe the standard of care treatment options with a focus on IAC, which is administered in interventional radiology. It also highlights important nursing issues including the administration of chemotherapy in a clinical area where it is not traditionally administered and the challenges faced in caring for children and families with retinoblastoma.     

经皮支气管动脉/体动脉植入药物输注系统灌注化疗治疗中晚期肺癌初步探讨

目的：研究经皮支气管动脉／体动脉植入药物输注系统（DIS）灌注化疗治疗中晚期肺癌。方法：Seldinger＇s技术经右侧股动脉进路选择性肺癌供血体动脉造影后行超选择性插管并留置植入导管,连接植于右髂窝皮下囊的药盒组成DIS,经DIS进行灌注化疗。结果：3例晚期肺癌,分别采用4F-C2／Yashim超滑导管-ImplantofixⅡ／Soph-A-Port成功行左锁骨下动脉、右叶支气管动脉植入DIS,多次灌注化疗。结论：支气管动脉或供血体动脉植入DIS进行灌注化疗,是一种值得进一步研究应用的肺癌介入治疗方法。     

恶性脑胶质瘤术后嘧啶亚硝脲间质化疗同步放疗临床观察

目的 :探讨恶性脑胶质瘤术后嘧啶亚硝脲 (ACNU)间质化疗联合同步放疗的临床疗效。方法 :对 68例手术后恶性脑胶质瘤患者分成两组继续治疗 :A组 ( 38例 )行ACNU间质化疗联合同步放疗 ;B组 ( 30例 )行单纯放疗以作对照。所有病例均进行随访 ,近期效果用CT扫描比较。结果 :A组有效率 ( 86 8% )及 1、2、3a生存率 ( 92 1%、68 4%、5 0 0 % )明显高于B组 ( 2 6 6%及 5 0 0 %、16 6%、10 0 % ) (P <0 0 1)。两组均无明显毒副反应。结论 :恶性脑胶质瘤术后ACNU间质化疗联合同步放疗是一个安全有效的较佳选择治疗方案。     

Successful daptomycin lock therapy for implantable intra-arterial catheter infection in a patient with liver metastases of colon cancer

There are no data on how to manage implantable intra-arterial catheter (IAC) infections. We report the case of a patient with liver metastases of colon cancer treated by regional intra-arterial chemotherapy who presented a suspected IAC-related infection, in whom daptomycin systemic treatment and lock therapy allowed to cure the IAC infection.     

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis

ObjectiveTo undertake a meta-analysis of the treatment effects of different second-line chemotherapy regimens compared with FOLFIRINOX (FOL [folinic acid], F [fluorouracil], IRIN [irinotecan], OX [oxaliplatin]) after failure of gemcitabine-based first-line therapy in patients with pancreatic cancer.MethodsThis meta-analysis searched electronic databases, including Embase®, Medline, PubMed® and the Cochrane library, for eligible studies that reported the use of FOLFIRINOX and other drug regimens as second-line chemotherapy after failure of gemcitabine-based chemotherapy. Pooled analyses for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and grade 3/4 treatment-emergent adverse events (TRAEs) were undertaken.ResultsThe analysis included six studies with a total of 858 patients. Compared with the three other second-line regimens, FOLFIRINOX had a significantly longer PFS (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.52, 0.89) and OS (HR 0.71, 95% CI 0.59, 0.86); and a significantly better ORR (HR 0.43, 95% CI 0.23, 0.80) and DCR (HR 0.71, 95% CI 0.58, 0.88). However, grade 3/4 adverse events were more frequently reported in patients administered FOLFIRINOX compared with the other three regimens.ConclusionFOLFIRINOX is recommended as a second-line chemotherapy regimen for patients with pancreatic cancer that have failed on gemcitabine-based first-line therapy.Research Registry number: reviewregistry1300     

Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: A retrospective review

Background: Antiarrhythmic medications may be used chronically to prevent recurrences of cardiac arrhythmias. Vaughan Williams class I and class III antiarrhythmic drugs have the potential for serious adverse effects, some of which can result in significant morbidity or mortality. To provide early detection and prevention of adverse events, appropriate therapeutic monitoring has been suggested during amiodarone therapy.Objective: The objective of this study was to monitor antiarrhythmic drug therapy to improve the continuity and consistency of care for patients receiving class I or class III antiarrhythmic drugs.Methods: Patients receiving antiarrhythmic medications, including amiodarone, sotalol, dofetilide, and propafenone, were referred to an antiarrhythmic medications clinic (at an academic university), Columbus, Ohio, either at the time of hospital discharge or during an outpatient appointment with a cardiologist, for monitoring. A retrospective chart review was conducted in consecutive outpatients attending the clinic between July 2007 and April 2008. Antiarrhythmic medication monitoring protocols were developed for a pharmacy-based outpatient clinic by a collaborative effort between pharmacists, physicians, and nurses. Adherence to monitoring protocols was assessed, and the type and frequency of pharmacist-identified events and interventions were determined. Continuum of care for patients was facilitated by coordination of referral to specialty clinics (n = 11) or pharmacist contact with physicians (n = 40).Results: In all, 134 patients were included and were receiving amiodarone (n = 58), sotalol (n = 40), dofetilide (n = 28), or propafenone (n = 8). At enrollment, 59.0% of patients had completed all recommended laboratory and objective testing compared with 98.5% after the initial visit. Adherence to monitoring protocols was improved in patients receiving amiodarone, dofetilide, or propafenone, but not sotalol. Fifty-four patients had a return visit, and after follow-up visits, 100% of patients were current with testing. Pharmacist-identified events or interventions occurred during 38% of visits, including unrecognized adverse event detection (ie, pulmonary function decline, QT prolongation, laboratory abnormality) and clinically significant drug interaction identification. Amiodarone was associated with the highest rate of detected adverse events (23% of patient visits). A change in the antiarrhythmic medication regimen was recommended for 9 patients that later resulted in the discontinuation of therapy in 3 patients.Conclusion: Pharmacist monitoring of outpatient antiarrhythmic medication therapy appeared to improve patient adherence to recommended testing protocols and to help identify adverse events and clinically significant drug interactions     

白血病患者鞘内注射的护理干预

目的探讨护理干预对白血病患者鞘内注射化疗药物(鞘内化疗)的影响。方法将51例鞘内化疗的白血病患者随机分为干预组27例与对照组24例。两组均采用常规护理,干预组另加心理干预、行为干预、饮食干预。结果干预组患者的头痛、头晕、恶心、呕吐的发生率明显降低,程度明显减轻(P<0.01或P<0.05)。结论护理干预能明显降低白血病患者鞘内化疗的不良反应事件的发生,并可使其程度减轻。     

紫杉醇联合S-1的新辅助化疗方案在局部进展期胃癌中的疗效

目的:评价紫杉醇联合S-1方案的新辅助化疗治疗进展期胃癌的临床疗效及不良反应。方法:回顾性分析2014年7月至2017年7月在上海交通大学附属第六人民医院普外科接受治疗的55例进展期胃癌患者的临床资料。采用Kaplan-Meier法进行生存分析,Cox比例风险模型进行多因素预后分析。结果:新辅助化疗+手术组的R0切除率明显高于常规手术组(P<0.05);新辅助化疗+手术组的不良反应均可经对症处理后缓解,不影响治疗,停药后逐渐恢复。Cox比例风险模型显示:病理反应(P=0.002,RR=0.121,95%CI:0.014~0.453)、影像学疗效(P=0.009,RR=0.212,95%CI:0.076~0.478)和TNM分期(P=0.015,RR=1.712,95%CI:1.021~4.123)是影响新辅助化疗+手术组患者术后复发的独立因素。新辅助化疗+手术组的并发症发生率与常规手术组差异无统计学意义(P>0.05)。结论:紫杉醇联合S-1方案是一个针对进展期胃癌新辅助化疗效果较好而不良反应较小的方案。     

参附注射液联合剂量密集化疗治疗老年晚期胃癌的临床观察

目的:探讨参附注射液联合剂量密集化疗治疗老年晚期胃癌的临床疗效。方法:将70例老年晚期胃癌患者按随机数字表分为对照组34例和治疗组36例。对照组采用常规剂量密集化疗,治疗组在此基础上联合参附注射液治疗。比较两组近期疗效、KPS疗效、毒副反应等指标。结果:两组缓解率、疾病控制率比较,差异无统计学意义(P>0.05),但治疗组KPS评分改善情况显著优于对照组(P<0.05),治疗组乏力、恶心呕吐、白细胞减少发生率明显低于对照组(P<0.05)。结论:参附注射液联合剂量密集化疗治疗老年晚期胃癌患者近期疗效肯定,且可降低患者化疗期间不良反应发生率,提高晚期胃癌老年患者的生活质量。     

Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF

BACKGROUND: Mobilization with chemotherapy and G-CSF may result in poor peripheral blood HPC collection, yielding <2 x 10(6) CD34+ cells per kg or <10 x 10(4) CFU-GM per kg in leukapheresis procedures. The best mobilization strategy for oncology patients remains unclear. STUDY DESIGN AND METHODS: In 27 patients who met either the CD34 (n = 3) or CFU-GM (n = 2) criteria or both (n = 22), the results obtained with two successive strategies-that is, chemotherapy and G-CSF at 10 microg per kg (Group 1, n = 7) and G-CSF at 10 microg per kg alone (Group 2, n = 20) used for a second mobilization course-were retrospectively analyzed. The patients had non-Hodgkin's lymphoma (5), Hodgkin's disease (3), multiple myeloma (5), chronic myeloid leukemia (1), acute myeloid leukemia (1), breast cancer (6), or other solid tumors (6). Previous therapy consisted of 10 (1-31) cycles of chemotherapy with additional chlorambucil (n = 3), interferon (n = 3), and radiotherapy (n = 7). RESULTS: The second collection was undertaken a median of 35 days after the first one. In Group 1, the results of the two mobilizations were identical. In Group 2, the number of CD34+ cells per kg per apheresis (0.17 [0.02-0.45] vs. 0.44 [0.11-0.45], p = 0. 00002), as well as the number of CFU-GM (0.88 [0.00-13.37] vs. 4.19 [0.96-21.61], p = 0.00003), BFU-E (0.83 [0.00-12.72] vs. 8.81 [1. 38-32.51], p = 0.00001), and CFU-MIX (0.10 [0.00-1.70] vs. 0.56 [0. 00-2.64], p = 0.001134) were significantly higher in the second peripheral blood HPC collection. However, yields per apheresis during the second collection did not significantly differ in the two groups. Six patients in Group 1 and 18 in Group 2 underwent transplantation, and all but one achieved engraftment, with a median of 15 versus 12 days to 1,000 neutrophils (NS), 22 versus 16 days to 1 percent reticulocytes (NS), and 26 versus 26 days to 20,000 platelets (NS), respectively. However, platelet engraftment was particularly delayed in many patients. CONCLUSION: G-CSF at 10 microg per kg alone may constitute a valid alternative to chemotherapy and G-CSF to obtain adequate numbers of peripheral blood HPCs in patients who previously failed to achieve mobilization with chemotherapy and G-CSF. This strategy should be tested in prospective randomized trials.     

不同新辅助化疗方案治疗进展期胃癌的临床研究

目的：比较ECF和FOLFOX新辅助化疗方案治疗进展期胃癌的疗效与毒副作用。方法：用ECF、FOLFOX化疗方案治疗进展期胃癌62例，3周为1个周期。所有患者完成3-4个周期新辅助化疗后评价疗效。ECF方案为表柔比星50mg／m2，第1天；亚叶酸钙（LV）200mg／m^2，第1—3天；5-氟尿嘧啶（5-Fu）600mg／m^2，第1—3天；顺铂20m异／m^2，第1-3天。FOLFOX方案为奥沙利铂100mg／m^2，静脉滴注2h，第1天；LV200mg／m^2，静脉滴注2h后推注5．Fu400mg／m^2，后续5-Fu1g／m^2。化疗泵持续48—72h恒速静脉输入，第1-2天。结果：ECF组的总有效率为37％（11／30），其中临床完全缓解（CR）3％（1例），部分缓解（PR）33％（10例），疾病稳定（SD）40％（12例）．疾病进展（PD）23％（7例），6例（20％）肿瘤TNM分期降低。FOLFOX组的总有效率为47％（15／32），其中CR3％（1例）．PR44％（14例）。SD34％（11例），PD19％（6例），10例（31％）TNM分期降低。两组白细胞下降、胃肠道反应相似：ECF组脱发程度较重，FOLFOX组外周感觉神经异常明显。结论：两组新辅助化疗方案对进展期胃癌均有效，毒性反应均可耐受。FOLFOX组疗效高于ECF组。     

Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever,rash, or neutropenia: A retrospective chart review

Background: Vancomycin has reliable antibacterial activity against many gram-positive pathogens but is associated with many adverse events. Teicoplanin, another glycopeptide, is associated with fewer adverse events, but its use in patients with previous vancomycininduced adverse reactions remains controversial.Objectives: The aims of this work were to evaluate the clinical characteristics of hospitalized patients with vancomycin-induced fever (ie, drug fever), rash, or neutropenia and to examine the tolerability of teicoplanin in these patients.Methods: This was a retrospective review of the medical charts of patients aged ≥18 years who were hospitalized between January 2002 and October 2007 at National Cheng Kung University Hospital in Tainan, Taiwan. Patients were included if they experienced drug-induced fever (ie, “drug fever”), rash, or neutropenia during vancomycin treatment. Their antimicrobial therapy was subsequently switched to teicoplanin. Clinical information and the development of drug fever, rash, or neutropenia with teicoplanin were determined from the charts.Results: Antibiotic therapy was switched to teicoplanin in 117 patients with vancomycin-induced fever alone (n = 24), rash alone (n = 77), both drug fever and rash (n = 8), or neutropenia (n = 8). The mean (SD) age of these patients was 53.1 (22.8) years, and 65 (56%) were male. The major clinical indications for vancomycin therapy among these patients were wound infections (21%), respiratory tract infections (14%), and bacteremia (13%). The dosages for vancomycin ranged from 1 g every 5 days to 1 g BID, and for teicoplanin ranged from 400 mg daily to 400 mg q72h, adjusted by the degree of renal dysfunction. Overall, 12 patients with vancomycin-induced fever (n = 2), rash (n = 6), or neutropenia (n = 4) subsequently developed teicoplanin-induced fever (n = 3), rash (n = 3), or neutropenia (n = 6). Specifically, of 8 patients with vancomycin-induced neutropenia, 4 (50%) subsequently developed neutropenia after switching to teicoplanin. Vancomycin- and teicoplanininduced neutropenia was often noted after 1 week of treatment. Among patients with vancomycin-induced fever, rash, or neutropenia, there were no differences between patients with or without teicoplanin-induced fever, rash, or neutropenia in terms of age, sex, weight, dosage or duration of vancomycin therapy, dosage of teicoplanin, or underlying disease. There was no difference in mortality rates between patients with or without teicoplanin-induced fever, rash, or neutropenia. The cause of all deaths was progression of infectious or underlying disease, unrelated to vancomycin or teicoplanin use.Conclusions: Based on this retrospective chart review of hospitalized patients with vancomycin-induced fever, rash, or neutropenia, only 10% experienced subsequent teicoplanin-induced fever, rash, or neutropenia. However, it should be noted that half of the patients with vancomycin-induced neutropenia developed teicoplanin-induced neutropenia.     

重组人血管内皮抑制素联合化疗治疗晚期肺腺癌患者的疗效及安全性

目的探讨重组人血管内皮抑制素联合化疗(培美曲塞+顺铂)治疗晚期肺腺癌的临床疗效,以及患者血清肿瘤标志物的变化及不良反应发生情况。方法选取汉中市中心医院肿瘤内科2017年1月至2019年1月收治的76例驱动基因阴性的晚期肺腺癌患者作为研究对象,36例对照组患者单纯采用化疗(培美曲塞+顺铂)进行治疗,40例试验组患者采用重组人血管内皮抑制素+化疗(培美曲塞+顺铂)进行治疗,对比两组患者临床疗效[客观缓解率(ORR)及疾病控制率(DCR)]和疾病无进展生存期(PFS)、治疗后血清肿瘤标志物水平及不良反应发生情况。结果试验组及对照组患者ORR分别为50.0%和27.8%,DCR分别为87.5%和66.7%,差异有统计学意义(χ^2=3.916、4.736,P<0.05)。试验组患者的PFS为(7.537±0.334)个月,显著高于对照组患者的(5.535±0.373)个月(t=14.187,P<0.05)。治疗后试验组患者糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)水平明显低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素联合化疗治疗晚期肺腺癌疗效显著,可延长患者PFS,降低肿瘤标志物水平,安全性良好,值得临床推广。     

Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer

Background

Neoadjuvant chemotherapy has been widely applied in treating advanced gastric cancer (GC). However, little research has been conducted on evaluating the effect of neoadjuvant chemotherapy. Purpose of this study was to evaluate the effect of SOX regimen as neoadjuvant chemotherapy by detecting some microRNAs.

Methods

Total 120 GC patients who had received neoadjuvant chemotherapy (SOX regimen) were recruited with 100 healthy participants as control contemporarily. Age and gender have no significant difference in both groups (P > .05). The effect of chemotherapy was evaluated by the results of CT scan and surgery. Also, adverse effects of chemotherapy were documented. Peripheral blood of GC patients was collected twice: one day before chemotherapy and surgery, respectively, whereas healthy controls’ peripheral blood was collected once. Quantitative real‐time PCR (qPCR) was utilized to detect expression of miR‐145, miR‐185, miR‐381, and miR‐195 of peripheral blood in both groups.

Results

One hundred and twenty patients with advanced GC completed a total of 386 cycles of neoadjuvant chemotherapy with effective rate at 84.17% (101 of 120). Expression of miR‐145, miR‐185, and miR‐381 of patients with GC was lower than that in the control group before chemotherapy commence (all P < .05), while the expressions of miR‐145 and miR‐185 elevated noticeably in CG patients after neoadjuvant chemotherapy (P < .05). The differences in the expression of miR‐145 and miR‐185 in advanced GC patients with different chemotherapy outcomes were detected.

Conclusion

Patients with GC at advanced stages had aberrant miRs expressions. Detection of miR‐145 and miR‐185 expression may assist to predict effectiveness and adverse effects of SOX regimen as neoadjuvant chemotherapy.